Head-to-head · WeighScore
Emerge Weight Loss vs Signos
The verdict
Signos takes it — 61.4/100 to 55.1/100.
Signos grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Signos (Signos+) is a metabolic-health platform that bundles clinician-prescribed compounded GLP-1 (semaglutide) with an FDA-cleared continuous glucose monitor (CGM) and app — pairing the medication with…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Emerge Weight Loss | Signos |
|---|---|---|
| WeighScore | 55.1/100 | 61.4/100 |
| Grade | C | C |
| Scorecard rank | #447 | #293 |
| Semaglutide | Not disclosed | $199/mo (6-month plan, compounded) |
| Tirzepatide | $287/mo (2.5 mg dose, compounded) | $199/mo (starting dose, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #447 · C
Strengths
- Tirzepatide-focused (largest effect-size compounded GLP-1)
- Wide dose range available
- Physician-supervised telemedicine model
Where it loses points
- Semaglutide is available only on request — the site and default plans are tirzepatide-only
- Less brand recognition than Henry Meds, Mochi, or SkinnyRx
Graded #293 · C
Strengths
- Bundles compounded GLP-1 (semaglutide) with an FDA-cleared CGM and app — glucose-guided weight loss, not just medication
- Starting at $199/mo on a 6-month program, with the CGM included at no extra cost
- Free rapid shipping; HSA/FSA eligible
- Real-time glucose insights and app coaching to help sustain results after GLP-1
Where it loses points
- Compounded GLP-1s are not FDA-approved finished products
- Headline price is a 6-month-program rate, not month-to-month
- Only semaglutide is shown in the program; tirzepatide availability is not confirmed
- Compounding pharmacy partner and state availability are not published on the landing page
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.